Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6115300 | 0.98 | GSK3B (0.34) | GSK3BALDH1A1L3MBTL1MEN1MAPT | |
| SCHEMBL3023228 | 0.74 | HSP90AA1 (0.39) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL6115783 | 0.74 | CYP1A2 (0.40) | ALDH1A1L3MBTL1 | |
| SCHEMBL2616850 | 0.71 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL5725699 | 0.67 | KDM4E (0.40) | GSK3BALDH1A1L3MBTL1MEN1MAPT | |
| SCHEMBL8349405 | 0.65 | IGF1R (0.38) | ALDH1A1L3MBTL1 | |
| Bromide SCHEMBL10859520 | 0.65 | KDM4E (0.39) | GSK3BALDH1A1L3MBTL1MEN1MAPT | |
| SCHEMBL16944044 | 0.65 | ALDH1A1 (0.31) | ALDH1A1L3MBTL1 | |
| SCHEMBL11292186 | 0.64 | GSK3B (0.35) | GSK3B | |
| SCHEMBL828058 | 0.64 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012068196-A1 | BIS HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | WO | disclosed |
| US-20120129897-A1 | BIS HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129897-A1 | BIS HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2012068196-A1 | BIS HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | WO | disclosed |
| US-4590299-A | 2-guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1986-05-20 | — | — | US | disclosed |
| US-4510313-A | 2-Guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0050458-B1 | 2-GUANIDINO-4-HETEROARYLTHIAZOLES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1985-01-02 | — | — | EP | disclosed |
| US-4452987-A | Haloacetyl imidazoles | PFIZER INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4374843-A | 2-Guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0050458-A2 | 2-Guanidino-4-heteroarylthiazoles and pharmaceutical compositions containing them | PFIZER INC. (US) | 1982-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129897-A1 | BIS HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP3, TIMP3, MMP9 | GSK3B 1930/4885ALDH1A1 560/4885L3MBTL1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.